Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
German Cancer Research Center · Heidelberg University · +5 more institutions
Abstract
Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types.
We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-1, and PD-L1 and pyrosequencing for assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status in 135 glioblastoma specimens (117 initial resection, 18 first local recurrence). PD-L1 gene expression was analyzed in 446 cases from The Cancer Genome Atlas.
Citation impact
- FWCI
- 22.02
- Percentile
- 100%
- References
- 58
Authors
17- ASAnna S. BerghoffCorresponding
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Comprehensive Cancer Center Vienna, University Hospital of Zurich, National Center for Tumor Diseases, Medical University of Vienna
- BKBarbara Kiesel
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Comprehensive Cancer Center Vienna, University Hospital of Zurich, National Center for Tumor Diseases, Medical University of Vienna
- GWGeorg Widhalm
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Comprehensive Cancer Center Vienna, University Hospital of Zurich, National Center for Tumor Diseases, Medical University of Vienna
- OROrsolya Rajky
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Comprehensive Cancer Center Vienna, University Hospital of Zurich, National Center for Tumor Diseases, Medical University of Vienna
- GRGerda Ricken
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Comprehensive Cancer Center Vienna, University Hospital of Zurich, National Center for Tumor Diseases, Medical University of Vienna
Topics & keywords
- PTEN
- Tensin
- Tumor-infiltrating lymphocytes
- CD20
- Cancer research
- CD8
- Immunohistochemistry
- PD-L1
- Good health and well-being